CIK 0001789972 · Non-accelerated filer<br>Smaller reporting company
Cullinan Therapeutics, Inc.
Sign in to watch- Ticker
- CGEM
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813879991
- Phone
- 617-410-4650
- Business address
- ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
- Former names
- Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $222,000
- in 2 filings, $222K under 10b5-1 plans
Net −$222,000. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-01-12 | Jovan-Embiricos Morana Director | Purchase | +104,762 | $21.00 | $2.2M | 104,762 |
| 2021-01-12 | Jovan-Embiricos Morana Director | Conversion · Series Seed Convertible Preferred Stock | −8,000,000 | 0 | ||
| 2021-01-12 | Jovan-Embiricos Morana Director | Conversion · Series A Convertible Preferred Stock | −20,500,000 | 0 | ||
| 2021-01-12 | Jovan-Embiricos Morana Director | Conversion · Series A Convertible Preferred Stock | −4,500,000 | 0 | ||
| 2021-01-12 | Jovan-Embiricos Morana Director | Conversion · Series B Convertible Preferred Stock | −3,205,128 | 0 | ||
| 2021-01-12 | Jovan-Embiricos Morana Director | Conversion · Series B Convertible Preferred Stock | −1,282,051 | 0 | ||
| 2021-01-12 | Jovan-Embiricos Morana Director | Conversion · Series C Convertible Preferred Stock | −503,988 | 0 | ||
| 2021-01-12 | Jovan-Embiricos Morana Director | Conversion · Series C Convertible Preferred Stock | −1,007,977 | 0 | ||
| 2021-01-12 | Jovan-Embiricos Morana Director | Conversion · Series C Convertible Preferred Stock | −503,988 | 0 | ||
| 2021-01-12 | Jovan-Embiricos Morana Director | Conversion · Series C Convertible Preferred Stock | −1,511,966 | 0 | ||
| 2021-01-12 | Trigilio Jeffrey Chief Financial Officer | Purchase | +2,250 | $21.00 | $47K | 2,250 |
| 2021-01-12 | Hughes Owen President and CEO | Purchase | +2,500 | $21.00 | $53K | 506,226 |
| 2021-01-07 | GADICKE ANSBERT Director | Other acquisition | +281,268 | 281,268 | ||
| 2021-01-07 | GADICKE ANSBERT Director | Other acquisition · Series Seed Convertible Preferred Stock | +1,136,525 | 1,136,525 | ||
| 2021-01-07 | GADICKE ANSBERT Director | Other acquisition · Series A Convertible Preferred Stock | +3,551,640 | 3,551,640 | ||
| 2021-01-07 | GADICKE ANSBERT Director | Other acquisition · Series B Convertible Preferred Stock | +2,276,692 | 2,276,692 | ||
| 2021-01-07 | GADICKE ANSBERT Director | Other acquisition · Series C Convertible Preferred Stock | +649,030 | 649,030 | ||
| 2021-01-07 | GADICKE ANSBERT Director | Other acquisition · Stock Option (Right to Buy) | +262,114 | 262,114 | ||
| 2021-01-07 | GADICKE ANSBERT Director | Other acquisition · Stock Option (Right to Buy) | +88,824 | 88,824 | ||
| 2021-01-07 | Baeuerle Patrick See Remarks | Grant or award · Stock Option (Right to Buy) | +286,665 | 286,665 |
Page 22 of 23 · 446 trades